Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 2
1952 1
1958 1
1959 1
1960 5
1961 1
1962 1
1963 1
1964 2
1976 3
1977 3
1978 5
1979 29
1980 76
1981 143
1982 182
1983 297
1984 436
1985 767
1986 1003
1987 1464
1988 1617
1989 1779
1990 1682
1991 1890
1992 1849
1993 1785
1994 2144
1995 1905
1996 2047
1997 1880
1998 2195
1999 1897
2000 1927
2001 2111
2002 1964
2003 2003
2004 2010
2005 2154
2006 1925
2007 1795
2008 1827
2009 1743
2010 1668
2011 1655
2012 1605
2013 1551
2014 1529
2015 1473
2016 1398
2017 1234
2018 1247
2019 1247
2020 1254
2021 1235
2022 1164
2023 1081
2024 1052
2025 390

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63,732 results

Results by year

Filters applied: . Clear all
Page 1
Cyclosporine-induced erythromelalgia.
Caiza-Zambrano F, Galarza J, Benetti M, Gonzalez F, Landriscina P, Reisin R, León-Cejas L. Caiza-Zambrano F, et al. Pract Neurol. 2023 Aug;23(4):343-345. doi: 10.1136/pn-2023-003770. Epub 2023 Jun 30. Pract Neurol. 2023. PMID: 37391230
We report a 42-year-old woman who developed erythromelalgia after taking cyclosporine for myasthenia gravis. Although exact mechanism for this rare adverse effect is unclear, it is reversible, and so clinicians should be aware of the association . Additional use of cortico …
We report a 42-year-old woman who developed erythromelalgia after taking cyclosporine for myasthenia gravis. Although exact mechanism …
Cyclosporine neurotoxicity.
Hauben M. Hauben M. Pharmacotherapy. 1996 Jul-Aug;16(4):576-83. Pharmacotherapy. 1996. PMID: 8840363 Review.
Studies and case reports on cyclosporine neurotoxicity in which individualized patient data were provided were included for review and analysis. ...Postulated mechanisms include a vasculopathy based on cyclosporine's effect on endothelial cell synthesis of pr …
Studies and case reports on cyclosporine neurotoxicity in which individualized patient data were provided were included for review an …
Cyclosporine analogues.
Jeffery JR. Jeffery JR. Clin Biochem. 1991 Feb;24(1):15-21. doi: 10.1016/0009-9120(91)90105-n. Clin Biochem. 1991. PMID: 2060128 Review.
Numerous analogues of cyclosporine A (CsA) have been produced and studied. Although these analogues have given considerable insight into structure-activity relationships, none have been shown to have the safety and efficacy of CsA. The most promising of these analogues is …
Numerous analogues of cyclosporine A (CsA) have been produced and studied. Although these analogues have given considerable insight i …
Cyclosporine: Immunosuppressive effects, entwined toxicity, and clinical modulations of an organ transplant drug.
Alqadi R, Alqumia A, Alhomoud IS, Alhowail A, Aldubayan M, Mohammed HA, Alhmoud H, Khan RA. Alqadi R, et al. Transpl Immunol. 2025 Feb;88:102147. doi: 10.1016/j.trim.2024.102147. Epub 2024 Nov 15. Transpl Immunol. 2025. PMID: 39549927 Review.
A recap of the immunosuppressive effects, and entwined toxicity of the drug, now relegated primarily to bone marrow early transplants, is being overviewed for the past protocols that were used to minimize, and avoid, or use this calcineurin inhibitor class of drug, cyclosporin …
A recap of the immunosuppressive effects, and entwined toxicity of the drug, now relegated primarily to bone marrow early transplants, is be …
Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.
Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, Weinstein G. Lebwohl M, et al. J Am Acad Dermatol. 1998 Sep;39(3):464-75. doi: 10.1016/s0190-9622(98)70325-1. J Am Acad Dermatol. 1998. PMID: 9738783 Review.
Neoral, a more consistently absorbed form of cyclosporine, has recently been approved by the Food and Drug Administration for the treatment of psoriasis. This report outlines the indications, contraindications, dosage recommendations, monitoring requirements, adverse event …
Neoral, a more consistently absorbed form of cyclosporine, has recently been approved by the Food and Drug Administration for the tre …
[Cyclosporine A in dermatology].
Thivolet J, Kanitakis J. Thivolet J, et al. Presse Med. 1991 Dec 21-28;20(44):2249-55. Presse Med. 1991. PMID: 1838166 Review. French.
Ciclosporin A (CsA) is a cyclic undecapeptide of fungal origin endowed with immunosuppressive properties but also active on cells outside the immune system, especially epidermal and hair-follicle keratinocytes. ...
Ciclosporin A (CsA) is a cyclic undecapeptide of fungal origin endowed with immunosuppressive properties but also active on cells out …
[Cyclosporine].
Paul C, Garat H. Paul C, et al. Ann Dermatol Venereol. 2011 Dec;138(12):836-8. doi: 10.1016/j.annder.2011.10.004. Epub 2011 Oct 29. Ann Dermatol Venereol. 2011. PMID: 22137622 French. No abstract available.
[Topical cyclosporine in ophthalmology: Pharmacology and clinical indications].
Levy O, Labbé A, Borderie V, Laroche L, Bouheraoua N. Levy O, et al. J Fr Ophtalmol. 2016 Mar;39(3):292-307. doi: 10.1016/j.jfo.2015.11.008. Epub 2016 Mar 17. J Fr Ophtalmol. 2016. PMID: 26997607 Review. French.
Cyclosporine A (CsA) is a cyclic undecapeptide, which is an immunosuppressive drug in the calcineurin inhibitor class. ...Many of its pharmacological effects on the ocular surface are direct consequences of its ability to inhibit T ciclosporine activation and apopto …
Cyclosporine A (CsA) is a cyclic undecapeptide, which is an immunosuppressive drug in the calcineurin inhibitor class. ...Many of its …
Cyclosporine in transplantation - a history of converging timelines.
Colombo D, Ammirati E. Colombo D, et al. J Biol Regul Homeost Agents. 2011 Oct-Dec;25(4):493-504. J Biol Regul Homeost Agents. 2011. PMID: 22217983 Review.
In 1978-79 the first successful results of the use of cyclosporine in kidney were reported. Cyclosporine was the first single drug able to control rejection. ...The present review focuses also on cyclosporine-based regimen of immunosuppression, adverse side e …
In 1978-79 the first successful results of the use of cyclosporine in kidney were reported. Cyclosporine was the first single …
Cyclosporin clinical pharmacokinetics.
Fahr A. Fahr A. Clin Pharmacokinet. 1993 Jun;24(6):472-95. doi: 10.2165/00003088-199324060-00004. Clin Pharmacokinet. 1993. PMID: 8513650 Review.
Cyclosporin is a powerful immunosuppressive drug used in transplantation medicine and to treat autoimmune diseases. ...Cyclophilin, a binding protein for cyclosporin, influences distribution of cyclosporin in the body. Despite its lipophilicity, cyclospori …
Cyclosporin is a powerful immunosuppressive drug used in transplantation medicine and to treat autoimmune diseases. ...Cyclophilin, a …
63,732 results
You have reached the last available page of results. Please see the User Guide for more information.